Competitive Intelligence | Pharma/Biotech Consulting | Research I Insights | Group Scrum Master
📢 Exciting news in the world of oncology! The US FDA has approved Ogsiveo (nirogacestat) tablets, the first-ever drug for treating adult patients with progressing desmoid tumors. These rare, non-cancerous, but locally aggressive tumors can invade surrounding structures and organs, causing pain, mobility issues, and decreased quality of life. 🎗 ↪ Historically, surgical removal has been the primary treatment, but the risk of recurrence and other health complications post-surgery has led to an increased focus on systemic therapies. 💉 💊 The approval of Ogsiveo is a significant step forward in addressing the unmet medical needs of patients with rare tumors. The drug demonstrated clinically meaningful and statistically significant improvement in progression-free survival compared to placebo in a pivotal clinical trial. 💯 🌈 The FDA granted Ogsiveo with Priority Review, Fast Track, Breakthrough Therapy, and Orphan-Drug designations. 💪 👏 Congratulations to SpringWorks Therapeutics Inc. on this remarkable achievement! 🙌 👉 For more information on this update, check out the link - https://lnkd.in/dsebtJPj #fda #approval #oncology #desmoidtumors #rarediseases #medicalbreakthroughs
